Skip to content
Review Open access

Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions

Oct 2026 · Current Oncology · Vol 33 · 0 citations · 114 references
Medicine

Abstract

Simple Summary Recurrence remains a major challenge after treatment intended to cure colorectal cancer, as small amounts of residual cancer may remain below the detection limits of imaging and routine blood tests. This review examined 94 publications evaluating whether small fragments of genetic material shed by cancer cells into the blood can detect residual disease, predict recurrence, and monitor treatment response. Across the literature, detection of cancer-derived genetic material after treatment was consistently associated with a higher risk of recurrence and poorer survival. Repeated blood testing generally improved detection and often identified signs of returning cancer approximately 2.5 to 11.5 months before standard surveillance methods. The studies used a wide range of testing methods, blood collection schedules, and biological signals, which limited direct comparison. Test performance also varied with cancer stage, the biological characteristics of the tumor, and the site of recurrence. Although these blood tests are highly promising for risk assessment and surveillance, current evidence does not show that changing treatment solely on the basis of a positive result improves survival. Further clinical trials and standardized testing methods are needed before routine use, but these approaches could eventually support earlier recurrence detection, more personalized follow-up, and avoidance of unnecessary treatment.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.